Australia markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
40.02+0.48 (+1.21%)
At close: 04:00PM EST
39.70 -0.32 (-0.80%)
After hours: 05:13PM EST
Full screen
Loading interactive chart…
  • Zacks

    Biogen (BIIB) Down on Medicare Draft Ruling for Alzheimer's Drugs

    Biogen (BIIB) stock declines after Medicare proposes covering FDA-approved Alzheimer's drugs like Aduhelm only for patients enrolled in qualifying clinical studies.

  • Motley Fool

    Where Will Cassava Sciences Be in 1 Year?

    First, the company produced strong results in clinical studies for its potential therapy for Alzheimer's disease (AD), Simufilam. The other reason is the result of Biogen, a competitor, receiving regulatory approval in the U.S. last year for its novel AD treatment -- the first such therapy approved for AD since 2003.

  • Motley Fool

    3 Healthcare Stocks That Could Rocket Higher in 2022

    A key clinical trial, an enormous market opportunity, and breakthrough biotechnology could drive returns for shareholders this year.